Keyphrases
Percutaneous Coronary Intervention
100%
Ticagrelor
100%
Confidence Interval
100%
Prasugrel
95%
Clopidogrel
90%
P2Y12 Inhibitors
60%
Myocardial Infarction
50%
Atrial Fibrillation
50%
ST-elevation Myocardial Infarction (STEMI)
50%
Registry Study
50%
Nationwide Registry
50%
Congestive Heart Failure
50%
Anthracyclines
50%
Classical Hodgkin Lymphoma
50%
Hodgkin Lymphoma
50%
Matched Cohort Study
50%
Relative Risk
44%
Oral Anticoagulation
40%
Adriamycin
40%
Bleomycin
40%
Major Adverse Cardiovascular Events
35%
Absolute Risk
34%
Bleeding Risk
30%
Adjusted Hazard Ratio
30%
Medical Artificial Intelligence
25%
Decision Speed
25%
Vinblastine
20%
Prednisone
20%
Dacarbazine
20%
Doxorubicin-cyclophosphamide
20%
Procarbazine
20%
Etoposide
20%
Lymphoma Patients
20%
Relative Rate
20%
Radiotherapy
20%
Doxorubicin
20%
Multivariable Logistic Regression
15%
Repeat Revascularization
15%
Aspirin
15%
Recurrent Myocardial Infarction
15%
Hospitalization
15%
Effect Modelling
15%
Average Treatment Effect
15%
AIMS™
15%
Safety Outcomes
15%
National Cohort Study
10%
Efficacy Outcomes
10%
Gastrointestinal Bleeding
10%
Myocardial Infarction Treatment
10%
Elevation Change
10%
Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
100%
Ticagrelor
100%
Prasugrel
95%
Clopidogrel
90%
Cohort Study
60%
Heart Infarction
54%
Liver Disease
50%
ST Segment Elevation Myocardial Infarction
50%
Doxorubicin
50%
Anthracycline
50%
Hodgkin Disease
50%
Congestive Heart Failure
50%
Cardiovascular Disease
35%
Classical Hodgkin Lymphoma
31%
Bleomycin
25%
Brain Ischemia
20%
Bleeding
20%
Acetylsalicylic Acid
15%
Cyclophosphamide
12%
Prednisone
12%
Procarbazine
12%
Vinblastine
12%
Dacarbazine
12%
Etoposide
12%
Vincristine
12%
Elimination
10%
Anticoagulant Agent
10%
Proton Pump Inhibitor
10%
Antivitamin K
10%
Thrombocytopenia
10%
Direct Oral Anticoagulant
10%
Alcohol Liver Disease
10%
Medicine and Dentistry
Cohort Analysis
100%
Classical Hodgkin Lymphoma
81%
Doxorubicin
75%
Liver Disease
50%
Atrial Fibrillation
50%
Cardiovascular Disease
50%
Congestive Heart Failure
50%
Hodgkin's Lymphoma
50%
Anthracycline
50%
Anticoagulation
30%
Cumulative Incidence
25%
Hazard Ratio
25%
Bleomycin
25%
Brain Ischemia
20%
Diagnosis
12%
Patient Referral
12%
Awareness
12%
Charlson Comorbidity Index
12%
Vincristine
12%
Etoposide
12%
Radiation Therapy
12%
Vinblastine
12%
Cyclophosphamide
12%
Procarbazine
12%
Dacarbazine
12%
Prednisone
12%
Antithrombotic
10%
Vitamin K Antagonist
10%
Alcohol Liver Disease
10%
Direct Oral Anticoagulant
10%
Major Bleeding
10%
Drug Elimination
10%
Thrombocytopenia
10%
Cardiovascular System
6%
Population
6%
